Diagnostic, therapeutic and laboratory results; Documentation of urine drug tests and review of results with member; Evaluations and consultations; Prescription Monitoring Program reviews; Treatment of objectives; Discussion of risks and benefits; Informed consent; Treatments; 80.07 POLICIES AND PROCEDURES (cont.) Medications (including date, type, dosage, and quantity prescribed and/or dispensed to each patient); Instructions and agreements; Treatment planning updated ninety (90) days inclusive of nonpharmacologic therapy and non-opioid pharmacologic therapy, as appropriate; includes plan strategies to mitigate risk; and includes a plan of how therapy will be discontinued if benefits do not outweigh risks; and Records remain current and be maintained in an accessible manner and readily available for review. Buprenorphine and Buprenorphine Combination Products for Substance Use Disorder (SUD) MaineCare’s coverage of buprenorphine, a Schedule III narcotic, is subject to strict limitations on members qualified to receive the drug, regarding prior authorization, and clearly defined maximum daily dosages. MaineCare covers multiple formulations of the drug buprenorphine only for a member who has a diagnosis of Substance Use Disorder (SUD). All prescriptions for buprenorphine, buprenorphine derivatives, and naltrexone must be reported to the Maine Prescription Monitoring Program (PMP) pursuant to the rules established at 14-118 C.M.R. Chapter 11, Rules Governing the Controlled Substances Prescription Monitoring Program and Prescription of Opioid Medications. Covered Services MaineCare covers buprenorphine for a member who has a diagnosis of SUD. The medication must be prescribed by a practitioner who has obtained an XDEA identification number (which denotes buprenorphine prescriber status) from the U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control and meets all requirements as set forth in Maine statutes and Maine’s Office of Substance Abuse and Mental Health Services, Chapter 11, Rules Governing the Controlled Substances Prescription Monitoring Program (). Reimbursement for FDA-approved and Prescription of Opioid Medications buprenorphine products for opioid use disorder treatment as listed on the
Diagnostic, therapeutic and laboratory results; Documentation of urine drug tests and review of results with member; Evaluations and consultations; Prescription Monitoring Program reviews; Treatment of objectives; Discussion of risks and benefits; Informed consent; Treatments; 80.07 POLICIES AND PROCEDURES (cont.) Medications (including date, type, dosage, and quantity prescribed and/or dispensed to each patient); Instructions and agreements; Treatment planning updated ninety (90) days inclusive of nonpharmacologic therapy and non-opioid pharmacologic therapy, as appropriate; includes plan strategies to mitigate risk; and includes a plan of how therapy will be discontinued if benefits do not outweigh risks; and Records remain current and be maintained in an accessible manner and readily available for review. Buprenorphine and Buprenorphine Combination Products for Substance Use Disorder (SUD) MaineCare’s coverage of buprenorphine, a Schedule III narcotic, is subject to strict limitations on members qualified to receive the drug, regarding prior authorization, and clearly defined maximum daily dosages. MaineCare covers multiple formulations of the drug buprenorphine only for a member who has a diagnosis of Substance Use Disorder (SUD). All prescriptions for buprenorphine, buprenorphine derivatives, and naltrexone must be reported to the Maine Prescription Monitoring Program (PMP) pursuant to the rules established at 14-118 C.M.R. Chapter 11, Rules Governing the Controlled Substances Prescription Monitoring Program and Prescription of Opioid Medications. Covered Services MaineCare covers buprenorphine for a member who has a diagnosis of SUD. The medication must be prescribed by a practitioner who has obtained an XDEA identification number (which denotes buprenorphine prescriber status) from the U.S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control and meets all requirements as set forth in Maine statutes and Maine’s Office of Substance Abuse and Mental Health Services, Chapter 11, Rules Governing the Controlled Substances Prescription Monitoring Program and Prescription of Opioid Medications (). Reimbursement for FDA-approved buprenorphine products for opioid use disorder treatment as listed on the
c2s080.docx